Therapeutic potential of the sphingosine kinase 2 inhibitor opaganib Authors: Fuxun Huang, Peng Zhan, Xiujuan Shi, Yueyang Sun, Xingbo Song, Peilu Sun, Bo Liu Published: 2026 ABSTRACT Opaganib is a proprietary, host-directed, potentially broadly potent, first-in-class oral sphingosine kinase 2 (SphK2) selective inhibitor developed by RedHill Biopharma Tel Aviv, Israel. It is currently the most widely used selective SphK2 inhibitor. It simultaneously inhibits three sphingolipid-metabolizing enzymes in human cells—SphK2, dihydroceramide desaturase (DES1), and glucosylceramide synthase (GCS)—leading to depletion of sphingosine 1-phosphate (S1P), accumulation of ceramides and dihydroceramides, and suppression of key pro-survival pathways including pERK, pAKT, and NF-κB. These events promote autophagy, apoptosis, and disruption of viral replication. A large body of evidence indicates that SphK plays an important role in health and disease. This study reviews the role and mechanisms of opaganib effects as anticancer, anti-inflammatory, and antiviral agent. The latest research directions for opaganib are described as gastrointestinal acute radiation syndrome (GI-ARS), chemical exposure indications, and COVID-19, Ebola, and other viruses, providing new therapeutic ideas and considerations for future research and clinical trials. Abbreviationsabbreviationsfull namesabbreviationsfull namesSphK2sphingosine kinase 2JNKc-Jun N-terminal kinaseDES1dihydroceramide desaturase5-FU5-FluorouracilGCSglucosylceramide synthaseRRM2regulatory subunit M2GI-ARSgastrointestinal acute radiation syndromeMysmyelocytomatosis oncogenepERKendoplasmic reticulum stress-related kinasePDACPancreatic ductal adenocarcinomapAKTphosphorylated protein kinaseOxaoxaliplatinNFκBNuclear factor kappa-BERendoplasmic reticulumc-Mycmyelocytomatosis oncogeneSCIDserver combined immune-deficiencyARSacute radiation syndromeIRINirinotecanSphsphingosineTMZTemozolomideS1Psphingosine 1-phosphateTRAILtumor necrosis factor-related apoptosis inducing ligandBCL2B-cell lymphoma-2DIPGdiffuse pontine gliomaBCLXLB-cell lymphoma-XLMcl-1MCL1 apoptosis regulatorPAK1P21-Activated Kinase 1ACE2angiotensin-converting enzyme 2LIMK1LIM domain kinase 1 GeneIL-1βinterleukin-1betaMMmultiple myelomaIL-18interleukin-18MMPmitochondrial membrane potentialTNF-αtumor necrosis factor-αCIcombination indexIL-6interleukin-6mCRPCmetastatic castration-resistant prostate cancerIL-10interleukin-10ARSIandrogen receptor signaling inhibitorRArheumatoid arthritismCRPCMetastatic castration-resistant prostate cancerOAosteoarthritis4TRPV4transient receptor potential vanilloidIRionizing radiationALIAcute lung injuryTFG-βtransforming growth factor-betaARDSacute respiratory distress syndromeMPOMyeloperoxidaseNLRP3nucleotide-binding oligomerization domain-like receptor protein 3GI-ARSgastrointestinal acute radiation syndromeASCapoptosis-associated speck like protein containing a CARD Abbreviationsabbreviationsfull namesabbreviationsfull namesSphK2sphingosine kinase 2JNKc-Jun N-terminal kinaseDES1dihydroceramide desaturase5-FU5-FluorouracilGCSglucosylceramide synthaseRRM2regulatory subunit M2GI-ARSgastrointestinal acute radiation syndromeMysmyelocytomatosis oncogenepERKendoplasmic reticulum stress-related kinasePDACPancreatic ductal adenocarcinomapAKTphosphorylated protein kinaseOxaoxaliplatinNFκBNuclear factor kappa-BERendoplasmic reticulumc-Mycmyelocytomatosis oncogeneSCIDserver combined immune-deficiencyARSacute radiation syndromeIRINirinotecanSphsphingosineTMZTemozolomideS1Psphingosine 1-phosphateTRAILtumor necrosis factor-related apoptosis inducing ligandBCL2B-cell lymphoma-2DIPGdiffuse pontine gliomaBCLXLB-cell lymphoma-XLMcl-1MCL1 apoptosis regulatorPAK1P21-Activated Kinase 1ACE2angiotensin-converting enzyme 2LIMK1LIM domain kinase 1 GeneIL-1βinterleukin-1betaMMmultiple myelomaIL-18interleukin-18MMPmitochondrial membrane potentialTNF-αtumor necrosis factor-αCIcombination indexIL-6interleukin-6mCRPCmetastatic castration-resistant prostate cancerIL-10interleukin-10ARSIandrogen receptor signaling inhibitorRArheumatoid arthritismCRPCMetastatic castration-resistant prostate cancerOAosteoarthritis4TRPV4transient receptor potential vanilloidIRionizing radiationALIAcute lung injuryTFG-βtransforming growth factor-betaARDSacute respiratory distress syndromeMPOMyeloperoxidaseNLRP3nucleotide-binding oligomerization domain-like receptor protein 3GI-ARSgastrointestinal acute radiation syndromeASCapoptosis-associated speck like protein containing a CARD Abbreviations Introduction Opaganib is a cell-permeable aryl adamantane compound developed by RedHill Biopharma, [3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl) amide] (Fig. 1). Its structural molecular formula is C23H25ClN2O, and its molecular weight is 380.9160 [1]. Opaganib is an orally active, isozyme-selective SphK2 inhibitor that acts as a competitive inhibitor with a Ki of 9.8 μM for sphingomyelinase and attenuates S1P formation in cells [1]. A metabolism study revealed T1/2 of 1.40 h in blood samples from mice given 100 mg/kg opaganib (7 h) intravenously; pharmacokinetic testing of the drug administered 100 mg/kg (p.o.) showed lower peak plasma levels of opaganib, but the compound was much more persistent, possibly reflecting continued absorption from the gastrointestinal tract, with a maximum half-life of 4.50 h [2].Fig. 1The chemical structure of opaganib. The chemical structure of opaganib. Sphingolipids are important components of eukaryotic cell membranes and mediators of cellular signal transduction [3,4]. Many enzymes regulate sphingolipid synthesis and catabolism. For example, SphK kinase consists of two isozymes, SphK1 and SphK2, and SphK2 is the key enzyme for S1P synthesis [5]. Sph and S1P play important roles in cancer development; Sph mediates cell cycle arrest and induces apoptosis, and S1P promotes cell growth, migration, and invasion [6]. Numerous studies have demonstrated that SphK2 expression is upregulated in a variety of tumors and diseases [7], and opaganib exerts various biological functions, such as anticancer, anti-inflammatory, and antiviral effects, by inhibiting SphK2 and S1P. Opaginib also has therapeutic potential for cardiovascular diseases, neurological diseases, viral infection-related diseases, and cancer (Table 1).Table 1Research on opaganib in various diseases.Table 1Ref.Disease typesSpeciesOpaganib dosageMethod of opaganib administrationOutcomeIn vitro/in vivoPathways[8]Colorectal cancerHT-29 CT-116DLD-1HT-29 tumor-bearing nude mice model0.3-3 μM; 5 or 20 mg/kgAdd to the culture mediumand culturetogetherp.o.Inhibition of cellProliferationDramatically inhibited HT-29 xenograft growthIn vitroIn vivoopaganib→Cer↑→PP1A or PP2 ↑→AKT-mTOR↓→cell proliferation and viability↓[9]NeuroblastomaNeuro-2a K-N-SH K-N-AS K-N-MC, IMR32 K-H-(BE)NOD/SCID mice (6–8 weeks old)0-50 μM; 50 mg/kgCoculturep.o.Cells are killed by opaganib concentrations wellEffective suppression of tumor growth improve survivalrateIn vitroIn vivoopaganib→c-Myc↓Mcl-1 ↓PERK↓N-Myc↓→cell proliferation↓[10]Multiple MyelomaNCI-H929RPMI-8226Dox40MM.1ROPM1U266.Primary human CD138+ myeloma cells.NSG mice0-60 μM0-40 μM50 mg/kgAdd to the culture medium and culturetogetherCoculturei.p.Inhibition of cellProliferationInduces cytotoxic or cytostatic effects on MM cells.Inhibition of cell proliferation.Inhibit tumor growth, reducetumor volume and improve survivalrate.In vitroIn vivoopaganib→C-MYC↓ NOXA↑→Mcl-1↓→Apoptosis↓opaganib→BCL2↓→ABT-737↓→Apoptosis↓[11]Triple-Negative Breast CancerHuman breast carcinoma cell lines MDA-MB-231 and BT-549 the mouse breast cancer cell line 4T1.Female BALB/c mice.0-4 μM; 40 mg/kgPretreatmentp.o.Inhibition of cell proliferation and migrationInhibition of cell proliferation and migrationDecrease metastasisIn vitroIn vivoopaganib→SphK2/S1 P↓→PAK1↓LIMK 1↓Cofilin1↓→ metastasis↓[12]Anti-non-small cell lung cancerNSCLC cell lines (A549 460 1299)H460Anti-non-small cell lung cancer mice model0-80 μMPretreatmenti.p.Opaganib reduced proliferation in NSCLC cell linesOpaganib represses tumor growthIn vitroIn vivoopaganib→S1P↓ Cer↑→AKT ↓MAPK↓→Cell apoptosis↓[13]CholangiocarcinomaWITT uCCT1, EGI-1 Z and HuH28 IV2720-100 μMCocultureOpaganib induces autophagy in cholangiocarcinoma cellsIn vitroopaganib→STAT3 signaling↓→cell proliferation ↑and apoptosis↓[14]Primary EffusionLymphomaBCBL-1NOD/SCIDmice0-80 μM; 50 mg/kgCoculturei.p.Opaganib induces apoptosis in dose-dependent fashion for BCBL-1 cellsOpaganib significantly reduced tumor expansionIn vitroIn vivoopaganib→AKT↓NF-kB↓→ Cells apoptosis↓[15]Diffuse Intrinsic Pontine GliomaDIPG cell lines SF8628 SF77615-80 μMPretreatmentOpaganib reduces DIPG proliferation through inducing tumor cell apoptosis and intracellular ceramide productionIn vitroopaganib→S1P↓ Cer↑→IFITM1, KAL1↓→cell proliferation↓[16]Relapsed/refractory multiple myelomaEligible patients were ≥18 years of age and had RRMM after previous treatment with a proteasome inhibitor and an immunomodulatory agent.250-740 mg BIDp.o.SK2 inhibitor opaganib, may be a useful approach toward the treatment of RRMMIn vivoopaganib→The treatment of RRMM is effective[17]Human skin squamous cell carcinomaA431 skin SCC cell line primary human melanocytesA431 tumor-bearing nude mice0.1-0.33 μM; 1-3 μM; 10 mg/kgAdd to the culture medium and culturetogetherp.o.Opaganib to exert a significant anti-survival activityopaganib oral administration inhibits A431 tumor growth in nude mice.In vitroIn vivoopaganib→Cer↑→Akt-mTOR↓→cell proliferation and viability↓[18]Lung cancerA549 cells patient-derived primary lung cancer cells1-30 μmol/LCocultureOpaganib induced a time-dependent responseIt would require at least 48 h for opaganib (3e100 mmol/L) to exert significant anti-growth activity.Opaganib dose-dependently induced apoptosisIn vitroopaganib→ Cer↑→GCS↓→lung cancer cells proliferation↓[19]Androgen resistant prostate cancerPC-3 and LNCaP cells0.01-1000 μMAdd to the culture medium and culturetogetherOpaganib resulted in a 50 ± 8.4% decrease in androgen-resistant prostate cancer proliferation.Opaganib is a targeted prostate cancer therapeutic.In vitroopaganib→cell proliferation ↓[20]Endocrine therapy-resistant luminal and basal-A breast cancerMDA-MB-361 cellMDA-MB-468 cellMDA-MB-468 tumor-bearing nude mice0.1–10 μM; 50 mg/kgCoculturep.o.Inhibited colony formation in vitro (IC50: 4.88 μM)Reduced tumor volume (37.3% inhibition) and lung metastasis (60% reduction) in vivoIn vitroIn vivoopaganib→p-PI3K/AKT and p-ERK↓→breast cancer proliferation↓[21]Lupus NephritisMRL/lpr miceMRL/MpJ mice50 mg/kgp.o.S1P and dh-S1P levels in circulation were significantly reducedIn vivoopaganib→SK2↓→dh-S1P↓ S1P↓→Inhibition of inflammation[22]Acute lung injuryThe murine-derived macrophage line RAW264.7 human-derived monocyte cell line,THP-1 C57BL/6J mice0-50 μM; 20 mg/kgPretreatmenti.p.Opaganib decreased the accumulation of acetylated p53 protein and the activation of NLRP3 inflammasome, lowered infiltration of inflammatory cells, alleviated macrophage-evoked oxidative injury and inflammatory reaction in lung tissuesin vitroIn vivoopaganib→SK2↓→S1P↓→HDAC↑→acetylated p53 protein↓→NLRP3↓→reduces inflammatory reaction in lung tissues.[23]Coronavirus Disease 2019 Pneumoniapatients2 × 250 mgp.o.Improved WHO level in the scale for clinical improvement and in time to discharge. Opaganib is safe and well tolerated and suggests a potential benefit of opaganib across various clinically meaningful outcome measures in patients with COVID-19 pneumoniaIn vivoopaganib→improved WHO level in the scale for clinical improvement and in time to discharge.[24]Chronic dermatitisC57BL/6J miceTrpv4−/−mice and their WT littermates, Trpa1−/−; Trpv1−/−mice and their WT littermates50 μMTopical applicationOpaganib reduced 50% S1P abundance and CD-associated wiping and scratching, attenuated CD-associated skin barrier damage and the clinical severity of skin lesions, blocked epidermal thickening of CD model skinIn vivoopaganib→SphK2↓→S1P↓→TRPV1/TRPA1/TRPV4↓→Inhibition of chronic pain and itch[25]Particle-induced inflammation of RAW264.7RAW 264.7macrophages0.5-20 μMPretreatmentSuppressed tumor necrosis factor TNF-α and interleukin IL-6 production.In vitroopaganib→SphK2↓→TNF-α↓ IL-6↓[26]Radiation-induced lung inflammationC57BL/6 mice100 mg/kgp.o.Suppressed the elevation of lung TNF-α, reduced expression of IL-6, macrophage infiltration was reduced.In vivoopaganib→SphK2↓→S1P↓→TNFα↓ IL6↓→Inhibition of radiation-induced pulmonary inflammation[27]Influenza A virusWild-type C57BL/6 mice0.1 mg/kgTopical (intranasal) dripOpaganib protects mice from lethal IAV infection.In vivoopaganib→SphK2↓→lethal IAV infection↓[28]GI-Acute Radiation SyndromeC57BL/6 mice50-100 mg/kgp.o.In mice receiving 50 mg/kg opaganib, the lethality of both radiation doses was greatly reduced,. In mice receiving 100 mg/kg opaganib, lethality was almost eliminatedIn vivoopaganib→SphK2↓→S1P↓→cer↑→GI-Acute Radiation Syndrome↓[29]Acute Kidney InjuryC57BL/6 mice50 mg/kgp.o.Opaganib improves kidney function and prevents mortality following renal IRIn vivoopaganib→MPO activity↓→Acute Kidney Injury↓[1]Ulcerative ColitisC57BL/6 mice50 mg/kgp.o.Opaganib reduced colon damage and markers of inflammation including neutrophil infiltration and cytokine inductionIn vivoopaganib→S1P↓→TNFα (IL)-1β (IFN)-γ IL-6↓[30]PsoriasisC57BL/6 male mice25 μg/40 μlSurfactantOpaganib reduced psoriatic markers, including erythema, scaling and epidermal thickness, as well as the sizes of the inguinal lymph nodesand spleenIn vivoopaganib→S1P↓→cytokine signal-ling 1 blocked T helper type 17 differentiation↓→Psoriasis↓[31]Arthralgic febrile illnessHeLaU2OSHepG2MCF10A5-30 μMPretreatmentOpaganib inhibited CHIKV replication in HepG2 cellsIn vitroopaganib→Cer↑→inhibited CHIKV replication Table 1Research on opaganib in various diseases.Table 1Ref.Disease typesSpeciesOpaganib dosageMethod of opaganib administrationOutcomeIn vitro/in vivoPathways[8]Colorectal cancerHT-29 CT-116DLD-1HT-29 tumor-bearing nude mice model0.3-3 μM; 5 or 20 mg/kgAdd to the culture mediumand culturetogetherp.o.Inhibition of cellProliferationDramatically inhibited HT-29 xenograft growthIn vitroIn vivoopaganib→Cer↑→PP1A or PP2 ↑→AKT-mTOR↓→cell proliferation and viability↓[9]NeuroblastomaNeuro-2a K-N-SH K-N-AS K-N-MC, IMR32 K-H-(BE)NOD/SCID mice (6–8 weeks old)0-50 μM; 50 mg/kgCoculturep.o.Cells are killed by opaganib concentrations wellEffective suppression of tumor growth improve survivalrateIn vitroIn vivoopaganib→c-Myc↓Mcl-1 ↓PERK↓N-Myc↓→cell proliferation↓[10]Multiple MyelomaNCI-H929RPMI-8226Dox40MM.1ROPM1U266.Primary human CD138+ myeloma cells.NSG mice0-60 μM0-40 μM50 mg/kgAdd to the culture medium and culturetogetherCoculturei.p.Inhibition of cellProliferationInduces cytotoxic or cytostatic effects on MM cells.Inhibition of cell proliferation.Inhibit tumor growth, reducetumor volume and improve survivalrate.In vitroIn vivoopaganib→C-MYC↓ NOXA↑→Mcl-1↓→Apoptosis↓opaganib→BCL2↓→ABT-737↓→Apoptosis↓[11]Triple-Negative Breast CancerHuman breast carcinoma cell lines MDA-MB-231 and BT-549 the mouse breast cancer cell line 4T1.Female BALB/c mice.0-4 μM; 40 mg/kgPretreatmentp.o.Inhibition of cell proliferation and migrationInhibition of cell proliferation and migrationDecrease metastasisIn vitroIn vivoopaganib→SphK2/S1 P↓→PAK1↓LIMK 1↓Cofilin1↓→ metastasis↓[12]Anti-non-small cell lung cancerNSCLC cell lines (A549 460 1299)H460Anti-non-small cell lung cancer mice model0-80 μMPretreatmenti.p.Opaganib reduced proliferation in NSCLC cell linesOpaganib represses tumor growthIn vitroIn vivoopaganib→S1P↓ Cer↑→AKT ↓MAPK↓→Cell apoptosis↓[13]CholangiocarcinomaWITT uCCT1, EGI-1 Z and HuH28 IV2720-100 μMCocultureOpaganib induces autophagy in cholangiocarcinoma cellsIn vitroopaganib→STAT3 signaling↓→cell proliferation ↑and apoptosis↓[14]Primary EffusionLymphomaBCBL-1NOD/SCIDmice0-80 μM; 50 mg/kgCoculturei.p.Opaganib induces apoptosis in dose-dependent fashion for BCBL-1 cellsOpaganib significantly reduced tumor expansionIn vitroIn vivoopaganib→AKT↓NF-kB↓→ Cells apoptosis↓[15]Diffuse Intrinsic Pontine GliomaDIPG cell lines SF8628 SF77615-80 μMPretreatmentOpaganib reduces DIPG proliferation through inducing tumor cell apoptosis and intracellular ceramide productionIn vitroopaganib→S1P↓ Cer↑→IFITM1, KAL1↓→cell proliferation↓[16]Relapsed/refractory multiple myelomaEligible patients were ≥18 years of age and had RRMM after previous treatment with a proteasome inhibitor and an immunomodulatory agent.250-740 mg BIDp.o.SK2 inhibitor opaganib, may be a useful approach toward the treatment of RRMMIn vivoopaganib→The treatment of RRMM is effective[17]Human skin squamous cell carcinomaA431 skin SCC cell line primary human melanocytesA431 tumor-bearing nude mice0.1-0.33 μM; 1-3 μM; 10 mg/kgAdd to the culture medium and culturetogetherp.o.Opaganib to exert a significant anti-survival activityopaganib oral administration inhibits A431 tumor growth in nude mice.In vitroIn vivoopaganib→Cer↑→Akt-mTOR↓→cell proliferation and viability↓[18]Lung cancerA549 cells patient-derived primary lung cancer cells1-30 μmol/LCocultureOpaganib induced a time-dependent responseIt would require at least 48 h for opaganib (3e100 mmol/L) to exert significant anti-growth activity.Opaganib dose-dependently induced apoptosisIn vitroopaganib→ Cer↑→GCS↓→lung cancer cells proliferation↓[19]Androgen resistant prostate cancerPC-3 and LNCaP cells0.01-1000 μMAdd to the culture medium and culturetogetherOpaganib resulted in a 50 ± 8.4% decrease in androgen-resistant prostate cancer proliferation.Opaganib is a targeted prostate cancer therapeutic.In vitroopaganib→cell proliferation ↓[20]Endocrine therapy-resistant luminal and basal-A breast cancerMDA-MB-361 cellMDA-MB-468 cellMDA-MB-468 tumor-bearing nude mice0.1–10 μM; 50 mg/kgCoculturep.o.Inhibited colony formation in vitro (IC50: 4.88 μM)Reduced tumor volume (37.3% inhibition) and lung metastasis (60% reduction) in vivoIn vitroIn vivoopaganib→p-PI3K/AKT and p-ERK↓→breast cancer proliferation↓[21]Lupus NephritisMRL/lpr miceMRL/MpJ mice50 mg/kgp.o.S1P and dh-S1P levels in circulation were significantly reducedIn vivoopaganib→SK2↓→dh-S1P↓ S1P↓→Inhibition of inflammation[22]Acute lung injuryThe murine-derived macrophage line RAW264.7 human-derived monocyte cell line,THP-1 C57BL/6J mice0-50 μM; 20 mg/kgPretreatmenti.p.Opaganib decreased the accumulation of acetylated p53 protein and the activation of NLRP3 inflammasome, lowered infiltration of inflammatory cells, alleviated macrophage-evoked oxidative injury and inflammatory reaction in lung tissuesin vitroIn vivoopaganib→SK2↓→S1P↓→HDAC↑→acetylated p53 protein↓→NLRP3↓→reduces inflammatory reaction in lung tissues.[23]Coronavirus Disease 2019 Pneumoniapatients2 × 250 mgp.o.Improved WHO level in the scale for clinical improvement and in time to discharge. Opaganib is safe and well tolerated and suggests a potential benefit of opaganib across various clinically meaningful outcome measures in patients with COVID-19 pneumoniaIn vivoopaganib→improved WHO level in the scale for clinical improvement and in time to discharge.[24]Chronic dermatitisC57BL/6J miceTrpv4−/−mice and their WT littermates, Trpa1−/−; Trpv1−/−mice and their WT littermates50 μMTopical applicationOpaganib reduced 50% S1P abundance and CD-associated wiping and scratching, attenuated CD-associated skin barrier damage and the clinical severity of skin lesions, blocked epidermal thickening of CD model skinIn vivoopaganib→SphK2↓→S1P↓→TRPV1/TRPA1/TRPV4↓→Inhibition of chronic pain and itch[25]Particle-induced inflammation of RAW264.7RAW 264.7macrophages0.5-20 μMPretreatmentSuppressed tumor necrosis factor TNF-α and interleukin IL-6 production.In vitroopaganib→SphK2↓→TNF-α↓ IL-6↓[26]Radiation-induced lung inflammationC57BL/6 mice100 mg/kgp.o.Suppressed the elevation of lung TNF-α, reduced expression of IL-6, macrophage infiltration was reduced.In vivoopaganib→SphK2↓→S1P↓→TNFα↓ IL6↓→Inhibition of radiation-induced pulmonary inflammation[27]Influenza A virusWild-type C57BL/6 mice0.1 mg/kgTopical (intranasal) dripOpaganib protects mice from lethal IAV infection.In vivoopaganib→SphK2↓→lethal IAV infection↓[28]GI-Acute Radiation SyndromeC57BL/6 mice50-100 mg/kgp.o.In mice receiving 50 mg/kg opaganib, the lethality of both radiation doses was greatly reduced,. In mice receiving 100 mg/kg opaganib, lethality was almost eliminatedIn vivoopaganib→SphK2↓→S1P↓→cer↑→GI-Acute Radiation Syndrome↓[29]Acute Kidney InjuryC57BL/6 mice50 mg/kgp.o.Opaganib improves kidney function and prevents mortality following renal IRIn vivoopaganib→MPO activity↓→Acute Kidney Injury↓[1]Ulcerative ColitisC57BL/6 mice50 mg/kgp.o.Opaganib reduced colon damage and markers of inflammation including neutrophil infiltration and cytokine inductionIn vivoopaganib→S1P↓→TNFα (IL)-1β (IFN)-γ IL-6↓[30]PsoriasisC57BL/6 male mice25 μg/40 μlSurfactantOpaganib reduced psoriatic markers, including erythema, scaling and epidermal thickness, as well as the sizes of the inguinal lymph nodesand spleenIn vivoopaganib→S1P↓→cytokine signal-ling 1 blocked T helper type 17 differentiation↓→Psoriasis↓[31]Arthralgic febrile illnessHeLaU2OSHepG2MCF10A5-30 μMPretreatmentOpaganib inhibited CHIKV replication in HepG2 cellsIn vitroopaganib→Cer↑→inhibited CHIKV replication Research on opaganib in various diseases. The host-directed effects of opaganib are thought to involve the inhibition of multiple pathways, the induction of autophagy and apoptosis, and the disruption of viral replication through the simultaneous inhibition of three sphingolipid-metabolizing enzymes (SphK2, DES1, and GCS) in human cells. Opaganib results in the depletion of S1P in tumor cells, the elevation of ceramides, and the inhibition of signaling through endoplasmic reticulum stress-related kinase (pERK), phosphorylated protein kinase (pAKT), and Nuclear factor kappa-B (NFκB), promoting autophagy and/or apoptosis [13,14,[32], [33], [34]]. Opaganib also downregulates myelocytomatosis oncogene (c-Myc) expression in various tumor cell lines [10,[33], [34], [35], [36]] and inhibits DES1, increasing dihydroceramide levels and promoting autophagy [2,33]. Furthermore, opaganib exerts anti-inflammatory effects in several rodent models [1,37,38]. Recent large-scale reviews have underscored the complex, context-dependent roles of the SphK/S1P axis in cancer immune editing and resistance to immunotherapies. Sukocheva et al. highlighted how cancer cells exploit the SphK/S1P/S1PR network to evade immune surveillance and resist tumor necrosis factor-α (TNF-α)-induced apoptosis, positioning SphK inhibition as a strategy to overcome immunotherapy resistance [39]. Complementary work further detailed the involvement of SphK/S1P signaling in inflammatory gastrointestinal diseases and cancers, linking chronic inflammation, dysbiosis, and malignancy, and validating SphK as a tractable therapeutic target [40]. These contemporary perspectives provide a critical framework for understanding opaganib's mechanism of action beyond direct enzyme inhibition, emphasizing its potential as a host-directed agent that modulates both tumor cell survival and the inflammatory tumor microenvironment. In summary, opaganib is a proprietary investigational host-directed and potentially broadly potent agent confirmed from its experimental development pathway (Fig. 2). Opaganib is a first-in-class, orally administered selective inhibitor of SphK2 with anticancer, anti-inflammatory, and antiviral effects targeting a wide range of potential diseases, including obesity-associated syndromes, prostate cancer, cholangiocarcinoma, GI-ARS, sulfur mustard exposure, COVID-19, Ebola, and other viral pandemic pathogens(https://www.redhillbio.com/news/news-details/2024/RedHill-Announces-Collaboration-with-a-Leading-U.S.-Academic-Medical-Center-to-Develop-Opaganib-as-a-Countermeasure-Against-Phosgene-Inhalation-Injury/default.aspx).Fig. 2Major events across 15 years of opaganib research. Crohn's disease, cholangiocarcinoma, breast cancer, prostate cancer, multiple myeloma, COVID-19 pneumonia, GI-ARS. Pink: routine trials; blue: clinical trials; green: popular studies. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) Major events across 15 years of opaganib research. Crohn's disease, cholangiocarcinoma, breast cancer, prostate cancer, multiple myeloma, COVID-19 pneumonia, GI-ARS. Pink: routine trials; blue: clinical trials; green: popular studies. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) Opaganib has recently been selected for evaluation by two U.S. government programs on acute radiation syndrome (ARS) and sulfur mustard gas exposure countermeasures (RedHill Biopharma - RedHill's Opaganib Selected by the NIH Radiation and Nuclear Countermeasures Program). Opaganib has demonstrated antiviral activity against SARS-CoV-2, multiple variants, and several other viruses (e.g., influenza A and Ebola). The safety of opaganib in patients infected with these viruses has been demonstrated in a phase 2/3 multinational, randomized, placebo-controlled study enrolling 475 adult subjects hospitalized for severe COVID-19; opaganib has also been demonstrated safe in patients requiring hypoxia supplementation (62% reduction in ventilation and mortality) [41,42]. Opaganib has received orphan drug designation from the Food and Drug Administration for the treatment of neuroblastoma and cholangiocarcinoma and has undergone phase II clinical studies in advanced cholangiocarcinoma (NCT03377179) and prostate cancer (NCT03377179). An investigational phase Ⅰ radiotherapy regimen for opaganib has been developed in preparation for submission of Food and Drug Administration - Investigational New Drug application. This article reviews research progress from 2006 to 2024 on the therapeutic mechanism and pharmacological effects of opaganib and provides experimental evidence for its clinical development. Opaganib in tumors Opaganib is an oral small molecule inhibitor that exerts its antitumor effects by selectively targeting SphK2 [1]. SphK2 is a key enzyme in the sphingolipid metabolic pathway that catalyzes the phosphorylation of sphingosine (Sph) to form sphingosine 1-phosphate (S1P), which has been shown to play an important role in the development of a variety of malignant tumors through the modulation of cell proliferation, survival, migration, and the immune microenvironment [43]. Opaganib activates proapoptotic pathways (e.g., the mitochondrial pathway and caspase cascade) by inhibiting SphK2 activity, leading to sphingosine accumulation and decreased S1P levels, while inhibiting prosurvival signals (e.g., the ERK and ATK pathways), which ultimately induces apoptosis and inhibits the proliferation of tumor cells [32,44,45]. Preclinical studies have shown that opaganib exhibits broad-spectrum antitumor activity in a wide range of solid tumors and hematological malignancies. For example, in hepatocellular carcinoma models, opaganib inhibits tumor growth [46] and enhances the efficacy of sorafenib by downregulating the SphK2/S1P axis; in prostate cancer, opaganib delays the progression of desmoplasia resistance by modulating the androgen receptor signaling pathway [19]; and in colorectal cancer, opaganib reverses oxaliplatin resistance when used in conjunction with chemotherapy agents [47]. In addition, opaganib has a pleiotropic effect on the tumor microenvironment: on the one hand, it inhibits angiogenesis by decreasing the M2 polarization of tumor-associated macrophages; on the other hand, it enhances the T-cell-mediated antitumor immune response by inhibiting the S1P-mediated immune escape mechanism [48]. These immunomodulatory properties extend opaganib's therapeutic potential beyond direct cytotoxicity, positioning it as a candidate for combination with immune checkpoint inhibitors. Clinical studies have further validated the potential of opaganib. Phase I/II trials have shown that opaganib is well tolerated in patients with advanced solid tumors, with grade 1–2 gastrointestinal reactions being the main adverse effects [49]. Early trials in cholangiocarcinoma and diffuse large B-cell lymphoma patients showed partial remission and stable disease, suggesting its single-agent activity [50,51]. Opaganib is a potentially promising tumor and cancer therapeutic agent that may achieve therapeutic efficacy by inhibiting cancer cell growth and metastasis and promoting cancer cell death. In addition, conventional anticancer drugs can enhance opaganib's sensitivity and synergistic anticancer effects in some refractory animal and cellular tumor models (Fig. 3). The following sections detail the mechanistic insights. Detailed experimental conditions are provided in Table 1.Fig. 3Relevant studies on opaganib in cancer. Opaganib inhibits the growth of cholangiocarcinoma, neuroblastoma, and breast cancer cells. Opaganib induces death in human squamous cell carcinoma of the skin and multiple myeloma and inhibits the metastasis of breast cancer cells. In multiple myeloma, prostate cancer, and colon cancer, opaganib in combination with conventional anticancer drugs has also been shown to enhance drug sensitivity and exert synergistic anticancer effects. Relevant studies on opaganib in cancer. Opaganib inhibits the growth of cholangiocarcinoma, neuroblastoma, and breast cancer cells. Opaganib induces death in human squamous cell carcinoma of the skin and multiple myeloma and inhibits the metastasis of breast cancer cells. In multiple myeloma, prostate cancer, and colon cancer, opaganib in combination with conventional anticancer drugs has also been shown to enhance drug sensitivity and exert synergistic anticancer effects. Opaganib in cholangiocarcinoma Inhibition of cholangiocarcinoma proliferation In cholangiocarcinoma, opaganib inhibits signal transducer and activator of transcription 3 (STAT 3) phosphorylation, one of the key signaling pathways regulating the proliferation and survival of cholangiocarcinoma cells. The cell lines tested (WITT, HuCCT 1, EGI-1, OZ, and HuH 28) demonstrated inhibited growth in a dose-dependent manner after opaganib treatment at different concentrations for 72 h, as determined by BrdU ELISA (Table 1). The IC50 values for opaganib ranged from 36.3 to 48.6 μM. Moreover, opaganib significantly reduced the number of viable colonies of HuCCT-1 and EGI-1 cytosol [13]. Opaganib reduced the proliferation of six cholangiocarcinoma cell lines (HuH 28, HuCCT 1, WITT, EGI-1, OZ, and LIV 27), and in another study, Xiwei Ding et al. evaluated its effects on two other cholangiocarcinoma cell lines, RBE and HCCC 9810. Cholangiocarcinoma cells were exposed to increasing concentrations of opaganib for 72 h, and cell proliferation was evaluated via BrdU ELISA. Opaganib inhibited the proliferation of RBE and HCCC 9810 cells in a dose-dependent manner, with IC50 values of 33.03 and 42.49 μM, respectively [52]. Collectively, these data establish STAT3 as a critical downstream target of SphK2 signaling in cholangiocarcinoma and demonstrate consistent antiproliferative activity across multiple cell lines. Induction of cholangiocarcinoma cell death In cholangiocarcinoma, Xiwei Ding et al. reported that WITT cells were treated with 20–60 μM opaganib for 72 h. Apoptosis was then measured via Annexin V-FITC/PI labeling followed by flow cytometry, revealing a dose-dependent increase in caspase 3 and PARP cleavage in WITT cells after opaganib treatment. Treatment of WITT, HuCCT-1, and EGI-1 cells with 40 μM opaganib for 24 h and determination of the localization of LC3 (an autophagosome marker) via fluorescence microscopy revealed a significant increase in the percentage of cells at the LC3 site [13]. To further characterize opaganib-induced cytotoxicity, Xiwei Ding et al. assessed apoptosis by DAPI staining. After 72 h of treatment, opaganib induced apoptosis in all the CCA cell lines in a dose-dependent manner. The induction of apoptosis was verified by double staining of WITT cells with the V/PI membrane-bound protein. The BCL 2 protein family, which includes pro- and antiapoptotic proteins, is a major apoptosis regulator. The expression of several common genes in the BCL 2 family, including NOXA and BAX, was assessed in RBE and HCC 9810 cells via real-time qPCR, and opaganib was shown to upregulate the expression of proapoptotic NOXA in cholangiocarcinoma cells [52]. Notably, the concurrent induction of autophagy appeared to serve a cytoprotective function, as combination with the autophagy inhibitor chloroquine enhanced apoptosis. This observation highlights the importance of context-dependent autophagy modulation in optimizing opaganib's therapeutic efficacy. Inhibition of cholangiocarcinoma metastasis A cell migration test was performed via the IBIDI wound healing test. Cholangiocarcinoma cell lines were embedded for 24 h via IBIDI 35 mm 2-well microdishes, and the proliferation of CCA cells was determined via a migration assay at 0, 12, and 24 h. Reduced cell migration was observed when HuCCT1 cells were treated with a combination of WX-UK1 (upamostat metabolite) and opaganib [50], suggesting a potential role in limiting metastatic spread (Table 1). Combination of opaganib in the treatment of cholangiocarcinoma In cholangiocarcinoma, Xiwei Ding et al. demonstrated that opaganib in combination with CQ (autophagy inhibitor) lowered the proliferation of WITT, HuCCT 1, EGI-1, and OZ cells, as shown by a BrdU ELISA. CQ significantly enhanced opaganib-induced apoptosis, as demonstrated by DAPI staining for apoptosis assessment [13]. In cholangiocarcinoma, Xiwei Ding et al. used different concentrations of opaganib or ABT-263 (B-cell lymphoma-2/B-cell lymphoma-XL inhibitors) alone or in combination to treat RBE, HCCC 9810, and HuH 28 cells for 72 h. The results of cell viability detection by the CCK-8 assay demonstrated that opaganib inhibited the growth of cholangiocarcinoma cells and enhanced the antitumor effect of the B-cell lymphoma-2(BCL2)/B-cell lymphoma-XL (BCL-XL) inhibitor ABT-263 through NOXA-mediated degradation of MCL1. The combination of opaganib with the BCL2/BCL-XL inhibitor ABT-263 may provide a new strategy for the treatment of cholangiocarcinoma [52]. Faizal Z et al. coadministered opaganib (50 mg/kg) and upamostat (70 mg/kg) in mice with cholangiocarcinoma, which significantly inhibited tumor growth compared with that achieved with upamostat alone or opaganib alone by decreasing trypsin 1/3 (PRSS 1/3) and SphK2. The combination of the two treatments resulted in greater growth inhibition and a reduction in tumor volume [50]. These combination strategies offer promising avenues for overcoming intrinsic resistance in cholangiocarcinoma. Opaganib in breast cancer Inhibition of breast cancer proliferation James W. Antoon et al. examined Ki-67 (a protein marker of proliferation) in MCF-7 cells and stained the nuclei with DAPI. To determine whether opaganib reduces cancer cell proliferation, MCF-7 cells were treated with DMSO (vector) or ABC294640 for 48 h. The cells were then fixed with 3.7% formaldehyde in PBS, permeabilized with cold methanol, and incubated with an anti-Ki-67 antibody (red). Before imaging, the cells were washed with PBS and subjected to DAPI (blue) nuclear staining. Three independent experiments were performed, and in vitro immunostaining revealed that ABC294640 possessed potent antiproliferative properties and significantly reduced Ki-67 expression. Compared with the control, 10 μM treatment reduced Ki-67 staining by 89.34 ± 1.79% (P < 0.001) [53]. Induction of breast cancer cell death In breast cancer, opaganib inhibited apoptosis in basal-A triple-negative breast cancer cells, with the exception that, in an in vitro study, apoptosis in opaganib-treated MDA-MB-468 cells increased by 12.09 ± 3.47-fold (P < 0.05). In the in vivo study, opaganib was injected subcutaneously into mice (Table 1). The MPA-MB-468 tumor volume in the gel was reduced by 37.3%. In basal-A triple-negative breast carcinoma cells, immunohistochemistry revealed reduced Ki-67 protein expression in the endpoint tumors of mice treated with opaganib. These results suggest that opaganib exerts desirable therapeutic potential by inhibiting basal-A tumor proliferation and inducing apoptosis [20]. Inhibition of breast cancer metastasis Opaganib inhibits breast cancer cell metastasis. Weiwei Shi et al. confirmed that TNBC cells (MDA-MB-231, BT-549) had reduced migratory ability after exposure to 12.5 μM opaganib for 24 h via RT‒PCR and Western blot assays. In addition, SphK2/S1P might regulate TNBC cell migration in a P21-Activated Kinase 1 (PAK1)/LIM domain kinase 1 Gene (LIMK1)/cofilin1 signaling-dependent manner, and protein blotting revealed that the phosphorylation level of PAK1/LIMK1/cofilin1 was reduced in TNBC cells subjected to different treatments. The migratory capacity of MDA-MB-231 and BT-549 cells mediated by SphK2/S1P also significantly decreased. Opaganib reduced the lung metastasis of TNBC cells in a constructed 4T1 xenograft mouse model. Established size-matched 4T1 tumor-bearing mice were divided into two groups and treated with opaganib or the loaded drug. There was no significant difference in tumor weight between the two groups at the end of the experiment, whereas the number and size of lung metastatic nodules in the drug-loaded control group significantly increased at the end of the treatment, suggesting that opaganib reduces TNBC metastasis in vivo [11]. Notably, the dissociation between primary tumor growth and metastatic burden underscores opaganib's potential as an anti-metastatic agent. Opaganib in multiple myeloma Inhibition of multiple myeloma cell proliferation Jagadish Kummetha Venkata et al. incubated multiple myeloma (MM) cell lines (NCI-H929, OPM1, U266, RPMI-8226, RPMI-8226-Dox40, MM.1R, and MM.1S) with 30 μM opaganib medium. A viable cell counting assay revealed that opaganib significantly inhibited the proliferation of MM cell lines except U266 cells, and an MTT assay revealed that opaganib significantly inhibited the proliferation of primary human CD138+ myeloma cells. In addition, Jagadish Kummetha Venkata et al. inoculated MM.1S myeloma cells from NSG mice treated with opaganib, which significantly inhibited the growth of MM.1S myeloma cell xenografts, significantly reducing tumor volume [10] (Table 1). The relative resistance observed in U266 cells suggests that baseline expression of certain survival factors may determine sensitivity to SphK2 inhibition. Induction of multiple myeloma cell death Loss of the mitochondrial membrane potential (MMP) is a hallmark of mitochondrial autophagy. Jian Wu et al. treated U266 and MM1.R cells with opaganib or shRNA-mediated SphK2 knockdown, then measured mitochondrial membrane depolarization using a JC-1 MitoProbe. With the mitochondrial membrane potential intact, JC-1 remains a monomer. However, upon mitochondrial membrane depolarization, JC-1 forms dimers and accumulates as aggregates. Induction of mitochondrial membrane depolarization by treatment with opaganib or genetic inhibition of SphK2 was demonstrated by increased JC-1 aggregates in the lower right quadrant of the flow cytometer. Next, the Seahorse XF assay was used to measure and quantify the rate of ATP production and the mitochondrial system in MM cells treated with opaganib. Opaganib decreased the rate of oxygen consumption and the extracellular potential of the mitochondrial system in a dose-dependent manner. This treatment also reduced extracellular acidification and significantly decreased ATP production and spare respiratory capacity in a dose-dependent manner, consistent with the induction of mitochondrial autophagy. Furthermore, this effect was blocked by the mitochondrial autophagy inhibitor bafilomycin (0.5 nM) in U266 and MM1.R cells treated for 48 h with opaganib. Treatment with bafilomycin reversed the inhibition of cell viability mediated by SphK2 inhibition [44]. These findings link SphK2 inhibition to PARK2-mediated mitophagy and suggest that mitochondrial dysfunction is a key effector mechanism in MM. Combination of opaganib in the treatment of multiple myelomas Yubin Kang et al. used combination index (CI) calculations via CompuSyn software to confirm that the combination of 15 μmol/L opaganib and 3 μmol/L ABT-199 synergistically inhibited the proliferation of MM in MM cell lines (CI < 1, CIs <1 are considered synergistic). In addition, MM (JJN 3, 0 p.m. 2, and RPMI 8226) cells were exposed to opaganib (15 μmol/L) or ABT-199 (3 μmol/L) alone or in combination for 16 h. The number of apoptotic cells was measured via flow cytometry using membrane-bound protein-BIV staining, and the results indicated that opaganib in combination with ABT-199 synergistically induced the apoptosis of MM cells. Finally, in an in vivo study, JJN 3 cells were inoculated into NSG mice, and opaganib and ABT-199 were administered (Table 1). Protein blotting of in vivo tumor samples confirmed that the combination treatment significantly reduced Mcl-β 1, c-Myc, Bcl-β 2, and Bcl-β xL expression, leading to a significant reduction in MM tumor growth in vivo [54]. Yuko Tanaka et al. demonstrated significantly reduced MM cell line growth when opaganib (25 μM) was used in combination with 5 nM carfilzomib compared with 5 nM carfilzomib alone, and the combination of opaganib (25 μM) and 5 nM carfilzomib synergistically inhibited the growth of primary MM cells [55]. These data support the clinical evaluation of opaganib in combination with established anti-MM agents. Opaganib in prostate cancer Inhibition of prostate cancer proliferation Hea et al. evaluated the effects of opaganib (0, 10, 20, and 30 μM) on the viability of drug-resistant prostate cancer (TRAMP-2) cells via an MTT assay; opaganib inhibited the proliferation of these cells in a dose- and time-dependent manner [33]. Melissa McNaughton et al. coincubated opaganib (25 μM) with androgen-naïve prostate cancer cells (LNCaP-AI cells) for 30 min, and western blotting revealed reduced expression of the senescence markers p53 and p21 in these cells. Opaganib induced growth arrest in LNCaP-AI cells, modulating the follitropic and sphingolipid metabotropic pathways, thereby inducing growth arrest [56]. Matthew M. Gestaut et al. reported an antiproliferative effect of opaganib on androgen-resistant prostate cancer, with 28 μM opaganib used to treat PC-3 cells for 48 h. After treatment, the cells were fixed and stained with anti-Ki67 (Ki-67 is actively expressed at all cell cycle stages and provides insight into cancer mitotic activity); opaganib resulted in an 8.4–50% reduction in the proliferation of androgen-resistant prostate cancer cells compared with that of the controls. These results demonstrate the potential of opaganib as a therapeutic agent for androgen therapy-resistant prostate cancer [19]. Combination of opaganib in the treatment of prostate cancer Substantial progress has been made in the treatment of metastatic castration-resistant prostate cancer (mCRPC) over the past decade with the advent of novel androgen receptor signaling inhibitor (ARSI) regimens. However, therapeutic resistance to ARSIs remains a major clinical problem in patients with metastatic castration-resistant prostate cancer (mCRPC). Lin et al. reported that opaganib targets ceramide inhibition and that the S1P axis enhances mCRPC death [57], suggesting that sphingolipid modulation may circumvent ARSI resistance. A phase II study evaluating opaganib in combination with darolutamide in mCRPC is currently ongoing (NCT04207255). Opaganib in colorectal cancer Inhibition of colorectal cancer proliferation Opaganib has antiproliferative activity in colorectal cancer. The human CRC cell lines HT-29, HCT-116, and DLD-1 were treated with different concentrations of opaganib, and cell growth was detected via the MTT assay. The results showed that the inhibition of CRC cell lines by opaganib was time- and dose-dependent. Opaganib required at least 48 h to exert antiproliferative effects on HT-29 cells; moreover, opaganib treatment reduced the number of HT-29 colonies, as shown by Annexin V FACS analysis and histone-DNA ELISA. The results demonstrated that opaganib induced significant apoptosis in HT-29, HCT-116, and DLD-1 cells. Low-dose opaganib versus high-dose opaganib (Table 1) significantly reduced tumor growth, leading to a significant reduction in volume in HT-29 hormonal nude mice, in addition to a significant increase in the survival rate of opaganib-administered mice [8]. Induction of colorectal cancer cell death Opaganib-mediated activation of the c-Jun N-terminal kinase (JNK) pathway in CRC cells has a pro-apoptotic effect. The effect of opaganib on apoptosis in HT-29 cells was tested by Cai Xun et al. Annexin V FACS analysis and histone-DNA ELISA analysis revealed that opaganib induced significant apoptosis in HT-29 cells. In addition, the LDH content in the conditioned medium of opaganib-treated cells increased. Similar apoptotic and LDH results were observed in two other CRC cell lines (HCT-116 and DLD-1). Furthermore, opaganib has been tested for cytotoxicity against primary human CRC cells, indicating strong cytotoxic effects [8]. Combination of opaganib in the treatment of colorectal cancer HT-29 cells were treated with 5-Fluorouracil (5-FU, 5 μM) or cisplatin (5 μM) alone or in combination with opaganib (0.3 μM) for 72 h. Cell death was assessed via an MTT assay, and cell death was evaluated using an LDH release assay. Administration of 5-FU or cisplatin alone at the tested concentration only moderately inhibited growth, whereas coadministration of low concentrations of opaganib (0.3 μM) significantly increased sensitivity. Moreover, the LDH assay results revealed that opaganib significantly promoted 5-FU- and cisplatin-induced HT-29 cell death [8]. In the treatment of colorectal cancer, the role of PLX 4032 (a small-molecule inhibitor of the mutant BRAFV 600 E protein) in the treatment of transplanted BRAF-mutated CRC is unfortunately less effective because of the high incidence of rapidly evolving chemoresistance. Still, a significant increase in the expression level of SphK 2 was found after exposure to PLX 4032. The combination of opaganib and PLX 4032 is a potential novel therapeutic approach to counteract vemurafenib resistance in BRAF-mutant colon cancer [45]. These results position opaganib as a potential adjuvant to overcome chemoresistance in CRC. Opaganib in pancreatic cancer Combination of opaganib in the treatment of pancreatic cancer Pancreatic cancer remains challenging to treat, with a mortality-to-morbidity ratio of 0.94. The main reason for this high mortality rate is the cancer's resistance to gemcitabine, the main chemotherapeutic agent used to treat this disease. The combination of opaganib and gemcitabine can potentially treat cells harboring ribonucleotide reductase regulatory subunit M2 (RRM2) and myelocytomatosis oncogene (Mys) aberrations. Cell survival quantification using an SRB assay revealed that opaganib potentiated the effects of gemcitabine on pancreatic cancer cells. Western blotting results demonstrated that opaganib inhibited the Rb phosphorylation-mediated regulation of c-Myc and decreased RRM2 expression [36]. Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is resistant to current therapies, including oxaliplatin (Oxa). S1P is an antiapoptotic, prosurvival mediator affecting cellular functions, such as endoplasmic reticulum (ER) stress. Opaganib inhibits SphK2 and S1P, potentiating ER stress and improving the therapeutic response to Oxa in patients with PDAC [58]. These findings highlight the potential of opaganib to overcome two major resistance mechanisms in pancreatic cancer. Opaganib in human skin squamous cell carcinoma Inhibition of human skin squamous cell carcinoma proliferation Opaganib has antiproliferative activity in human skin squamous carcinoma. Cultured A431 cells (in complete medium) were treated with different concentrations of opaganib. MTT viability assays revealed that opaganib dose- and time-dependently inhibited the survival of A431 cells (Table 1). Western blotting revealed a significant increase in the activity of both caspase-3 and caspase-9 in opaganib treated A431 cells. Two primary human skin SCC cell lines (“Pri Can-1/2”) treated with opaganib (1 mM, 48 h) demonstrated apoptotic activation and an increase in the percentage of apoptotic cell nuclei (Hoechst staining assay). In in vivo experiments, oral administration of opaganib reduced A431 tumor volume in male nude mice [17]. Opaganib in neuroblastoma Combination of opaganib in the treatment of neuroblastoma In neuroblastoma, Lynn W. Maines et al. conducted in vivo experiments in which SK-N-(BE)2 NB cells were injected into immunodeficient server combined immune-deficiency (SCID) mice, and the mice were treated with opaganib (Table 1). The growth rate of tumors in mice treated with oral opaganib was significantly reduced. Opaganib was administered orally, 5 days per week, and irinotecan (IRIN) and Temozolomide (TMZ) (5 and 25 mg/kg, respectively) were administered by intraperitoneal injection, including a 5-day dosing/2-day withdrawal regimen. Tumor volume and body weight were measured daily for at least two complete cycles. Compared with opaganib- or IRIN + TMZ-treated mice, opaganib + IRIN + TMZ-treated mice had a significantly greater median survival rate [9], supporting the evaluation of opaganib as part of multi-agent regimens in high-risk neuroblastoma. Opaganib in the ovaries Inhibition of ovarian proliferation In ovarian cancer, Keqi Song et al. reported that opaganib (50 μM) treatment of EOC cells (an ovarian epithelial carcinoma cell line) for 48 h resulted in a significantly lower percentage of cells in the S phase than that in the control group, as determined via analysis of the cell cycle by flow cytometry. The expression levels of the cell cycle-related proteins cyclin D1, P-Rb, and cyclin B1 were significantly reduced in a dose-dependent manner, as determined by Western blot analysis. In addition, opaganib-induced apoptosis in EOC cells was detected by Annexin V-FITC/PI double staining [59]. Opaganib in lung cancer Inhibition of lung cancer cell proliferation in vitro Shuhong Guan et al. used an MTT assay to calculate the survival rate of A549 lung cancer cells. Opaganib required at least 48 h to exert significant antigrowth activity. The growth of A549 cells was inhibited in a dose- and time-dependent manner. A549 cells were treated with different concentrations of opaganib (Table 1) for 7 days and stained with crystal violet. Cell colonies were counted, and the quantitative results revealed that 3–30 μmol/L opaganib inhibited A549 colony formation. These results suggest that opaganib may inhibit the growth of lung cancer cells by targeting SphK2 [18]. Induction of lung cancer cell death Opaganib dose-dependently induced apoptosis and elevated the expression of cleaved caspase-3 and cleaved caspase-9 in A549 cells, as shown by the TUNEL assay and histone DNA apoptosis ELISA, confirming that opaganib-induced apoptosis and cytotoxicity may be dependent on lung cancer cell caspase activation. In addition, GCS siRNA knockdown similarly enhanced opaganib-induced cytotoxicity and apoptosis. GCS inhibition could enhance opaganib-induced antitumor cell activity [18]. Combination of opaganib in the treatment of lung cancer In lung cancer, Jie Yang et al. combined opaganib (10 μM) and TNF- Related Apoptosis Inducing Ligand (TRAIL) (20 ng/ml, a tumor necrosis factor-associated apoptosis-inducing ligand) compared with opaganib and TRAIL alone, and coadministration of opaganib and TRAIL was demonstrated to promote cell death in A549 and H1299 cells via the MTT assay. The synergistic induction of apoptosis by the combination of opaganib and TRAIL was confirmed by Annexin V-FITC/PI flow cytometry. Treatment with the combination of opaganib and TRAIL strongly stimulated cysteine-3 and cysteine-8 cleavage in A549 and H1299 cells, as shown by western blotting. In conclusion, opaganib enhances TRAIL-induced exogenous apoptosis and cell death, and combination treatment with these drugs may lead to synergistic biological effects [60]. These findings suggest that opaganib may enhance the efficacy of TRAIL-based therapies in non-small cell lung cancer. Opaganib in other cancers In cervical cancer, opaganib induced G1‒S phase blockade and apoptosis in cervical cancer cells, and in vivo, opaganib administration inhibited C33 xenograft tumor growth in mice [61]. In hepatocellular carcinoma, in vivo experiments in a nude mouse transplanted tumor model of hepatocellular carcinoma treated with either regorafenib or opaganib alone revealed mild tumor suppression, whereas the combination of the two drugs significantly inhibited tumor growth. Measurements of tumor volume and weight also confirmed that coadministration of opaganib with regorafenib sensitized resistant cells to treatment [62]. Regarding brain cancer, opaganib treatment significantly inhibited diffuse pontine glioma (DIPG) cell growth by inducing intracellular pro-apoptotic ceramide production and apoptosis, and targeting sphingolipid metabolism may be a promising strategy to improve DIPG treatment [15]. Collectively, these findings underscore the broad therapeutic potential of SphK2 inhibition across diverse malignancies. Opaganib in viruses Opaganib is a selective SphK2 inhibitor that interferes with host cell lipid metabolism pathways by inhibiting sphingosine metabolism to S1P. The S1P signaling pathway is involved in the regulation of lipid membrane formation (e.g., the endoplasmic reticulum and lipid droplets) required for viral replication and may directly inhibit viral replication (e.g., SARS-CoV-2) [63]. The S1P pathway regulates the release of inflammatory factors (e.g., IL-6 and TNF-α), and opaganib may ameliorate the excessive inflammatory response in critically ill patients with COVID-19 by reducing the “cytokine storm” through the inhibition of S1P production [23]. Moreover, opaganib has broad-spectrum antiviral potential. In addition to SARS-CoV-2, opaganib has shown in vitro inhibitory activity against enveloped RNA viruses, such as Ebola, Zika, and influenza A viruses, and may inhibit a broad spectrum of host-dependent viruses by interfering with host lipid metabolism (RedHill Biopharma - RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study). Collectively, these observations position opaganib as a host-directed antiviral agent with activity across multiple viral families, leveraging its ability to modulate sphingolipid metabolism—a conserved pathway exploited by diverse viruses. Opaganib in COVID-19 The novel coronavirus pneumonia (COVID-19) caused by the SARS-CoV-2 virus resulted in a major outbreak beginning in 2019, posing a considerable challenge to human health and safety [64]. Although several effective antiviral drugs have been identified for mildly infected viruses, nothing can be done for severe viral infections. Sphingolipids regulate key pathological processes, including viral proliferation and pathological host inflammation [65]. In a study published by RedHill Biopharma, the opaganib compound was revealed to function by inhibiting three key enzymes in sphingolipid metabolism: SphK2, DES 1, and GCS (Fig. 4). This, in turn, produces antiviral effects. As opaganib has shown positive efficacy against COVID-19, further studies on the biochemical mechanisms of this activity are needed. Here, we focus on potential antiviral mechanisms directly related to the biochemical effects of opaganib (Fig. 5). These mechanisms—autophagy induction, apoptosis promotion, and endocytosis inhibition—represent convergent points where sphingolipid modulation intersects with viral life cycles.Fig. 4Multitargeted effects of opaganib on sphingolipid metabolism. Opaganib inhibits SphK2, decreasing S1P synthesis; DES1 elevates dihydroceramides; and GCS reduces hexosylceramides.Fig. 5The antivirus effects of opaganib. First, inhibition of the GCS by opaganib reduces hexose ceramide, which impairs the ability of the virus to enter target cells. Second, the inhibition of DES 1 by opaganib enhances dihydroceramide and promotes autophagy, which inhibits viral replication. Third, hexose ceramide is required for the endocytosis of ACE 2-bound viruses. Finally, SphK2 regulates several signaling pathways required for viral replication and the viral replication complex. Multitargeted effects of opaganib on sphingolipid metabolism. Opaganib inhibits SphK2, decreasing S1P synthesis; DES1 elevates dihydroceramides; and GCS reduces hexosylceramides. The antivirus effects of opaganib. First, inhibition of the GCS by opaganib reduces hexose ceramide, which impairs the ability of the virus to enter target cells. Second, the inhibition of DES 1 by opaganib enhances dihydroceramide and promotes autophagy, which inhibits viral replication. Third, hexose ceramide is required for the endocytosis of ACE 2-bound viruses. Finally, SphK2 regulates several signaling pathways required for viral replication and the viral replication complex. Induction of autophagy Autophagy is a conserved catabolic pathway activated in response to cellular stress that plays an important role in the stability of the intracellular environment, nutrient supply, and defense through lysosomal degradation of intracellular waste, destruction of organelles, and invasion of microorganisms [66]. Opaganib is a first-line clinical agent that targets sphingolipid metabolism by inhibiting three key enzymes in sphingolipid metabolism: SphK2, DES 1, and GCS. Viruses, including COVID-19, inhibit autophagy to promote their own replication; thus, the activation of autophagy can effectively limit viral replication [67]. Dihydroceramide has been shown to induce autophagy in viruses [[68], [69], [70], [71]]. By contrast, opaganib elevates dihydroceramide through the inhibition of DES 1 [33,56,72]. Opaganib also inhibits viral autophagy by suppressing the activation of the PI3K-AKT-MTOR pathway [73,74]. Thus, opaganib may counteract virus-mediated suppression of autophagy, restoring this intrinsic antiviral defense mechanism. Induction of apoptosis One mechanism that limits viral spread is the induction of apoptosis in infected host cells; thus, viruses often inhibit apoptosis to promote their replication [75]. SARS-CoV-2 activates signaling through NFκB, which inhibits apoptosis through two pathways [76]. Opaganib inhibits NFκB signaling pathway activation, thereby promoting viral apoptosis, and opaganib itself inhibits the expression of MCL1 apoptosis regulator (Mcl-1) [54,77] and survivin to promote apoptosis. Opaganib also promotes apoptosis in cancer cells both alone and in combination with TRAIL [60,78]. By relieving NFκB-mediated suppression of apoptosis, opaganib may facilitate the elimination of virus-infected cells. Inhibition of endocytosis Sphingolipids are abundant components of the extracellular surface of the plasma membrane and are required for endocytosis [79,80]. SARS-CoV enters cells via angiotensin-converting enzyme 2 (ACE2)-mediated pH-dependent endocytosis [81]. Thus, sphingolipids are required for SARS-CoV penetration into target cells. Exposure of the virus to cells increases GCS levels [80,82]. Opaganib inhibits GCS, and GCS activity is required for the entry of influenza virus [83] and thrombocytopenia syndrome virus [84] via endocytosis. Vitner et al. demonstrated that SARS-CoV-2 infection of Vero E6 cells significantly elevated sphingolipid and dihydrosphingosine levels and that similar increases occurred in virus-infected mice [79,85]. Opaganib inhibits GCS; hence, the ability to replicate SARS-CoV-2 may be reduced. Interfering with GCS-dependent endocytosis thus represents a barrier to viral entry that is less susceptible to mutation-driven resistance. Opaganib's role in influenza A Influenza virus outbreaks pose a serious threat to human health annually. In particular, influenza A virus (IAV) is genetically mutable and resistant to antiviral drugs [86]. Vaccines against influenza viruses must be deployed annually and are less effective than vaccines against other viruses. Therefore, it is important to identify new therapeutic targets that regulate influenza virus replication and are less susceptible to the high mutation rate of influenza viruses. Opaganib's targeting of host lipid metabolism, rather than viral proteins, offers a strategy less vulnerable to viral escape mutations. Opaganib affects IAV replication Chuan Xia et al. reported the role of opaganib in influenza A virus (IAV) and demonstrated its action via in vivo and in vitro experiments. In vitro experiments, after C57BL/6 (B6) model mice were intranasally infected with IAV and opaganib (Table 1), IAV infection was attenuated, as determined by comparing the survival time and body weights of experimental and control mice. The viral titers in the lungs of the infected mice were also measured, and the results showed that opaganib protects mice from lethal IAV infection by reducing viral replication in vivo [27]. These findings suggest that the antiviral activity of opaganib extends beyond SARS-CoV-2 to other respiratory RNA viruses. Opaganib in Ebola virus EVD is a serious and often fatal disease caused by the Ebola virus [87]. Currently, only a combination of three monoclonal antibodies, Inmazeb™ (atoltivimab, maftivimab, and odesivimab-ebgn, Regeneron Pharmaceuticals, Inc.), and the monocolonal antibodyEbanga™ (ansuvimab-zykl, RidgebackBiotherapeutics, LP) are approved by the FDA for EBOV treatment [88]. Both treatment options are intravenously administered, direct-acting monoclonal antibody antivirals that bind to glycoproteins on the surface of the Ebola virus to prevent the virus from entering human cells. There is an urgent need for host-directed small-molecule therapies that may be effective against multiple Ebola strains, are less likely to be affected by viral mutations, and are easy to store, distribute, and administer, especially in areas where healthcare access and infrastructure may be less than optimal. Opaganib is a novel, potentially broadly potent drug that has demonstrated antimutagenic antiviral and anti-inflammatory activity and may directly affect vascular health, which is one of the main targets of EBOV dysfunction. Opaganib is believed to be the first host-directed molecule to show anti-EBOV activity in vivo (RedHill Biopharma - RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola). Given its oral bioavailability and host-directed mechanism, opaganib addresses key limitations of current EBOV therapeutics. Opaganib trials for Ebola virus A U.S. Army study tested three doses of opaganib versus an inactive vector control group. The results of the in vivo study revealed an increase in the mean (SE) survival time of 11.2 (2.6) days in the opaganib group (P = 0.0279) compared with 5.5 (0.4) days in the inactive vector control group. A significant increase in survival time was observed in 30% of the mice in the 150 mg/kg treatment group compared with the vector control group. In addition, in an in vitro EBOV study funded and conducted by the U.S. Army, opaganib, in combination with raltegravir, was shown to significantly increase efficacy while maintaining cell viability. The results suggest the potential utility of combining opaganib with direct antiviral agents, such as raltegravir, to improve therapeutic outcomes and enhance efficacy while maintaining safety (RedHill and U.S. Army announce opaganib's Ebola Virus Disease survival benet in U.S. Army-Funded in vivo study) (Table 1). These preclinical data support further evaluation of opaganib, alone or in combination, for Ebola virus disease. Opaganib in inflammation Inflammatory responses are critically regulated by the sphingosine kinase/S1P axis. TNF-α, a master pro-inflammatory cytokine, activates SphK2, leading to increased S1P production, which in turn amplifies NF-κB signaling and sustains inflammation [39]. This feed-forward loop contributes to the pathogenesis of chronic inflammatory diseases and has been implicated in resistance to TNF-α-based immunotherapies. Conversely, inhibition of SphK2 disrupts this amplification loop, reducing S1P levels and dampening NF-κB-driven inflammatory gene expression [40]. Opaganib reduces intracellular and extracellular S1P levels by selectively inhibiting SphK2 and reducing the conversion of sphingosine to S1P, an important lipid signaling molecule involved in inflammation, immune cell migration, and angiogenesis [89,90]. S1P activates downstream proinflammatory pathways (e.g., NF-κB and MAPK) by binding to its receptors (S1PRs). Opaganib inhibits these pathways by decreasing S1P levels and reducing proinflammatory cytokines [91]. In sepsis and acute lung injury models, opaganib inhibited the assembly and activation of NLRP3 inflammatory vesicles and reduced the caspase-1-mediated release of interleukin-1beta (IL-1β) and the maturation of interleukin-18 (IL-18). Opaganib promotes macrophage conversion from the proinflammatory M1-type to the anti-inflammatory M2-type, decreases tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), and increases interleukin-10 (IL-10) expression [22]. These effects are consistent with the concept that SphK2 inhibition can reverse the pro-inflammatory phenotype driven by sustained TNF-α signaling. In the COVID-19 study, opaganib attenuated cytokine storm via the mechanisms described above while possibly inhibiting viral replication (e.g., by interfering with lipid membrane formation); however, the direct antiviral requires further validation. Some studies have suggested that opaganib mitigates oxidative stress-related inflammatory injury (e.g., acute lung injury models) by reducing ROS production [22,42]. Recent studies have shown that opaganib, a specific inhibitor of SphK2, has anti-inflammatory effects by inhibiting the signaling axis of SphK2/S1P. In chronic dermatitis, arthritis, colitis, hepatitis, nephritis, and pneumonia, opaganib achieves anti-inflammatory effects by reducing the expression of inflammatory factors (Fig. 6). Collectively, these data establish opaganib as a broad-spectrum anti-inflammatory agent with mechanisms encompassing inflammasome inhibition, macrophage polarization, and oxidative stress reduction. Importantly, by targeting the SphK2/S1P axis upstream of TNF-α signaling, opaganib offers a strategy to overcome TNF-α resistance mechanisms that limit the efficacy of current biologic therapies.Fig. 6Anti-inflammatory effects of opaganib. Opaganib achieves anti-inflammatory effects by reducing the expression of inflammatory factors in chronic dermatitis, arthritis, colitis, hepatitis, nephritis, and pneumonia. Anti-inflammatory effects of opaganib. Opaganib achieves anti-inflammatory effects by reducing the expression of inflammatory factors in chronic dermatitis, arthritis, colitis, hepatitis, nephritis, and pneumonia. Opaganib in arthritis Arthritis, highly prevalent worldwide, is a common chronic disease involving inflammatory lesions in the body's joints and surrounding tissues. There are more than 100 types of rheumatoid arthritis (RA), the most common of which are RA, osteoarthritis (OA), psoriatic arthritis, and inflammatory arthritis. The exact causes of arthritis are unknown, and there is no cure; thus, new therapeutic drugs must be developed [92]. Proinflammatory cytokines such as TNF-α activate SphK2. Thus, the inhibition of SphK2 may be a potential molecular target for treating rheumatoid arthritis [93]. In RA, TNF-α drives synovial inflammation and joint destruction through SphK2-dependent S1P production, creating a vicious cycle of inflammation. Leo R. Fitzpatrick et al. reported that opaganib exerts anti-inflammatory effects in RA by inhibiting SphK2 expression. Collagen-induced arthritis model mice were treated with opaganib. The mice had significantly reduced histological damage. Opaganib effectively inhibited T the TNF-α/NF-κB signaling pathways, a key driver of inflammation, thus contributing to the attenuation of disease pathogenesis observed in rodent models of RA [94] (Table 1). These findings suggest that SphK2 inhibition may disrupt the feed-forward loop of inflammation in RA. Opaganib in chronic dermatitis patients with persistent pain and itching Chronic dermatitis is a persistent state of skin inflammation, with pain and itching being among its most common and bothersome symptoms [95]. TNF-α is a key driver of skin inflammation in chronic dermatitis, and its effects are mediated in part through SphK2 activation and subsequent S1P signaling. Xinyu Zhang et al. recently identified the S1P/S1PRs-TRPV4 axis as a novel therapeutic target for persistent pain and itching in chronic dermatitis. In in vivo experiments, treatment of CD model mice with opaganib revealed that S1P abundance was reduced by approximately 50% in opaganib-treated CD skin compared with that in mediator-treated CD model skin. In addition, opaganib treatment significantly reduced the clinical severity of CD-associated skin barrier damage and skin lesions. Furthermore, opaganib treatment blocked epidermal thickening in CD model skin. Importantly, opaganib treatment significantly reduced CD-associated rubbing (166 ± 15.9 media vs. 107 ± 17.7 ABC) and scratching (159 ± 11.9 media vs. 83 ± 13.7 ABC). These findings suggest that in CD, increased S1P induces chronic pain and itching partly through transient receptor potential vanilloid (4TRPV4). Inhibition of S1 P synthesis or the S1P/S1P receptor-TRPV4 pathway is a promising therapeutic strategy for treating CD-associated pain and itching [24]. By reducing S1P downstream of TNF-α signaling, opaganib simultaneously addresses both the inflammatory and neurosensory components of chronic dermatitis. Opaganib's ability to simultaneously reduce inflammation and alleviate sensory symptoms highlights its dual therapeutic potential in chronic dermatologic conditions. Opaganib in acute lung injury (ALI) Acute lung injury (ALI) is a serious lung disease that is an acute hypoxic respiratory insufficiency resulting from damage to the alveolar‒capillary membrane caused by a variety of direct and indirect injury-causing factors, resulting in interstitial and alveolar edema; this disease is an early stage of acute respiratory distress syndrome (ARDS) [96]. TNF-α plays a central role in the pathogenesis of ALI/ARDS, where it amplifies neutrophil recruitment, macrophage activation, and endothelial barrier disruption. SphK2 is upregulated in response to TNF-α in lung tissues, contributing to sustained inflammation. Opaganib inhibition of SphK2 attenuates macrophage-induced oxidative damage and inflammatory responses in lung tissue. Linjing Gong et al. established a mouse model of acute lung injury via LPS induction. HE staining and inflammatory cell counts revealed that opaganib administration significantly attenuated LPS-induced lung injury, as evidenced by reduced hemorrhage and decreased alveolar wall thickness. Lung injury scores were also quantified for each group. There was a trend toward lower scores in the opaganib-treated group. In addition, LPS-induced tissue damage, inflammatory cell infiltration, and protein concentrations in the BALF were significantly reduced in opaganib-treated mice. Opaganib treatment ameliorated oxidative damage in the lung tissue. As macrophages are considered a major factor in the pathogenesis of ALI, treatment with opaganib reduces the infiltration of F4/80+ macrophages into lung tissue after exposure to LPS. Furthermore, blockade of SphK2 activity significantly induced M2 macrophage polarization. ELISA and WB results revealed that opaganib administration significantly reduced the expression levels of TNF-α, IL-6, IL-18, and IL-1, as well as those of nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3), apoptosis-associated speck like protein containing a CARD (ASC), and cleaved caspase-1. The levels of p53 acetylation and NLRP3 inflammasome activation in lung tissues were examined by immunoblotting and immunohistochemical staining, and opaganib treatment reduced p53 acetylation and NLRP3 expression [22]. In conclusion, opaganib limits oxidative stress and NLRP3 inflammatory vesicle activation by inhibiting the acetylation of p53, thereby preventing LPS-induced M1 macrophage polarization and the subsequent inflammatory cascade. SphK2 may be a potential therapeutic target for ARDS. These mechanistic insights position opaganib as a candidate for conditions characterized by macrophage-driven inflammation and inflammasome activation. These findings align with the concept that SphK2 inhibition attenuates TNF-α-driven inflammasome activation, a key pathogenic mechanism in ARDS. Opaganib inhibits radiation-induced lung inflammation and fibrosis Pulmonary fibrosis may occur as a result of exposure to toxins such as asbestos, coal dust, silica, and radiation, as well as autoimmune diseases or viral infections. Fibrosis is driven by the chronic activity of inflammatory cytokines [97]. Approximately 50% of patients undergoing cancer treatment are exposed to ionizing radiation (IR), and accidental exposure to IR from terrorist nuclear events increases the incidence of fibrosis. In particular, inflammatory cytokines’ action depends on the production of S1P by SphK, and interactions between sphingolipid metabolism and transforming growth factor-beta (TFG-β) responses have been demonstrated [98]. TNF-α is a key mediator of radiation-induced inflammation and fibrosis, and its effects are amplified by SphK2-dependent S1P production. In conclusion, SphK inhibitors demonstrate excellent potential to suppress acute inflammation and chronic inflammatory and fibrotic pathologies. Lynn W. Maines et al. [26] irradiated male C57BL/6 mice with a Varian linear accelerator at 16 Gy TBI (5% bone marrow shielding) and then administered 0 or 150 mg/kg opaganib (BID) twice a day (Groups B and C, respectively) for 5 days starting 24 h after irradiation (as in the case of accidently exposed victims using MCM). The study confirmed that treatment with opaganib strongly reduced the level of hydroxyproline in the lungs, and micro-CT imaging revealed less lung damage with opaganib. These data suggest that a single dose of opaganib prior to radiation has a protective effect on the development of pulmonary fibrosis. However, repeated doses of opaganib during the initial inflammatory phase after radiation appear to minimize the fibrotic cascade. A mouse model of chronic IR exposure was also constructed, and a single dose of opaganib after radiation was found to be insufficient to prevent lung inflammation by measuring TNFα in lung tissue. However, repeated doses of opaganib after radiation provided substantial protection against subsequent lung inflammation. An additional long-term study was conducted to compare the efficacy of opaganib administered as MCM during the initial inflammatory phase alone, during the delayed inflammatory phase alone, or during both phases (Table 1). Survival was monitored for 180 days. IL-6 and TNFα levels were significantly lower in the treatment group than in the control group. Myeloperoxidase (MPO) activity was also reduced in opaganib-treated mice. There was a highly significant (P = 0.008) improvement in survival on day 180 in the day 1–3 plus day 31–45 treatment groups (60% versus 10% in the control group). Treatment with opaganib significantly reduced the mean fibrosis score in the lungs of irradiated mice. In conclusion, opaganib is a viable candidate for clinical trials in patients at risk of lung inflammation and fibrosis [26]. These findings have dual relevance: as a medical countermeasure against accidental radiation exposure and as an adjunct to reduce radiation-induced toxicity in cancer radiotherapy. Opaganib in other diseases Opaganib inhibits radiation-induced gastrointestinal acute radiation syndrome (GI-ARS) IR induces the development of pathological inflammation, which can occur through accidental exposure (e.g., nuclear accidents or terrorist incidents) or anticipated exposure (e.g., cancer radiotherapy) [99,100]. Radiation-induced production of proinflammatory cytokines, such as IL-1β, TNFα, and IL-6, produces acute and chronic sequelae in tissues of the gastrointestinal tract, blood, and other tissues, particularly in the gastrointestinal tract, where radiation-induced GI-ARS occurs [[101], [102], [103]]. The activation of NF-κB by TNFα is dose-dependently inhibited by opaganib [2], and the effects of opaganib are associated with reduced levels of TNFα, IL-1β, IFN-γ, and IL-6, as well as reduced levels of S1P in the colon. In conclusion [1], opaganib has a therapeutic effect on GI-ARS in vivo due to its IR toxicity. In in vivo experiments, Lynn W. Maines et al. constructed a GI-ARS model in C57BL/6 mice with partially shielded (5% of the bone marrow) irradiation. They administered 100 and 300 mg/kg of opaganib 4 h prior to exposure to 15.25 Gy, which reduced the mortality rate to 16% and 4%, respectively (P < 0.01 for 300 mg/kg). In addition, the mortality rate of mice exposed to 16.0 Gy radiation and pretreatment with 100 or 300 mg/kg of opaganib was reduced to 48% and 20%, respectively (P < 0.05 and < 0.001). Since GI-ARS is a progressive injury, further studies evaluated the protective capacity of opaganib in mice when it was administered multiple times, with the carrier or opaganib administered 4 h (−4 h) before the mice were exposed to 15.25 or 16.0 Gy radiation (Table 1). In the mice that received 100 mg/kg opaganib, lethality was virtually eliminated, i.e., 0% and 4% at 15.25 and 16.0 Gy, respectively (P < 0.01 and < 0.001). Finally, a multidose experiment was performed in which the initial dose of opaganib was not administered until 24 h after radiation exposure. This model assessed the ability of opaganib to attenuate GI-ARS when immediate treatment was not available, and with multidose administration initiated after radiation exposure of 15.25 Gy (+24 h), the mortality rate of opaganib was reduced from 39% to 8% and 18% for opaganib at 50 and 100 mg/kg, respectively. Even at 16.0 Gy, which resulted in 82% mouse mortality, treatment with 50 or 100 mg/kg of opaganib initiated 24 h after radiation reduced mortality to 56–58%. Opaganib (100 mg/kg) was also shown to be effective in mice treated 4 h after radiation (+4 opaganib (100 mg/kg)) and provided significant protection (32% reduction in mortality; P < 0.05). The effect of the combination of standard treatment (radiotherapy + cisplatin) for head and neck cancer was also modeled, and opaganib in combination with TBI + cisplatin treatment had the greatest inhibitory effect on tumor growth [28]. These results demonstrate that opaganib provides robust protection against GI-ARS even when administration is delayed, a critical feature for medical countermeasure applications. Effects of Opaganib on phosgene inhalation injury Phosgene inhalation injury is the damage to the respiratory tract and lung tissue caused by phosgene when it is inhaled by humans. Phosgene (COCl2), a toxic gas that reacts with the mucous membranes of the respiratory tract and the moisture on the surface of the alveoli, triggering a series of pathophysiological changes, is a toxic chemical used mainly in industrial processes [104]. Phosgene has a distinctive odor similar to that of freshly cut grass or hay. At relatively high concentrations, phosgene inhalation can be extremely dangerous and even fatal. It is the cause of ARDS. No antidote or reversal agent exists. Phosgene was used primarily as a chemical weapon during the First World War. Today, phosgene is used ubiquitously in industry in the production of polymers, plastics, and pesticides. It is also used by some terrorists as a biological weapon. On 22 October 2024, RedHill Biopharma and Duke University School of Medicine signed a collaborative research agreement to determine whether opaganib potentially plays a protective role in limiting the damage caused by phosgene inhalation in animal models. Given opaganib's established efficacy in lung inflammation and ARDS models, this emerging indication warrants close attention. Opaganib clinical studies More than 400 people have been treated with opaganib in seven separate oncology and neocoronaryngitis clinical trials (summarized in Table 2; excluding unpublished trials). The following sections summarize the clinical experience across major indications.Table 2Clinical studies of opaganib.Table 2IDPhaseConditionsOfficial TitleSubjects TreatedIntervention/TreatmentPrimary ObjectiveNCT01488513ABC-101Phase IPancreatic CancerUnspecified Adult Solid Tumor, Protocol SpecificOpen-Label, Dose-Escalation,Safety, Pharmacokinetic and Pharmacodynamic Study of Opaganib in Patients with Advanced Solid Tumors21OpaganibTo assess safety and determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLT) of opaganib in patients with solid organ tumors.NCT02757326ABC-103Phase Ib/IIRefractory or RelapsedMultiple MyelomaA Phase Ib/II Safety and Efficacy Study of Opaganib in Patients With Refractory or Relapsed Multiple Myeloma Who Have Previously Been Treated With Proteasome Inhibitors and Immunomodulatory Drugs13OpaganibAssess overall treatment response rate and overall survival in patients with relapsed or refractory multiple myeloma treated with single-agent opaganib.NCT04207255ABC-107APhase IIProstateCancerA Phase II Study of the Addition of Opaganib to Androgen Antagonists in Patients With Prostate Cancer Progression on Enzalutamide or Abiraterone61OpaganibAbirateroneEnzalutamideTo measure the proportion of patients with disease control during opaganib (plus abiraterone or enzalutamide) therapy, using a composite metric based on PSA, bone scan, and RECIST measurements per Prostate Cancer Working Group3 (PCWG3) criteria. For purposes of this study, disease control is defined as stable disease or better after four cycles (16 weeks) of treatment.NCT03377179ABC-108Phase I/IIACholangiocarcinomaCholangiocarcinoma Non-resectableCholangiocarcinoma, PerihilarCholangiocarcinoma, ExtrahepaticCholangiocarcinoma, IntrahepaticStudy of Opaganib Alone and in Combination with Hydroxychloroquine Sulfatein the Treatment of Patients with Advanced,Unresectable Intra-hepatic, Perihilar and Extra-HepaticCholangiocarcinoma65OpaganibHydroxychloroquine Sulfate 200 MGPart 1: determine the Response Rate (RR) of cholangiocarcinoma defined as objective responses, ie complete and partial responses plus stable disease(SD) of at least 4 months to treatment with opaganib.Part 2: determine Durable Disease Control Rate (DCCR) of cholangiocarcinoma, defined as a DCR of at least a period of ≥4 4 months of treatment with opaganib and HCQ.NCT04414618ABC-110Phase IIACoronavirus InfectionsOpaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase 2a Study, in Adult Subjects Hospitalized With SARS-CoV-2 Positive Pneumonia22OpaganibPlaceboPhase 2a Proof of concept study. To assess the safety and tolerability of opaganib administered orally at 500 mg Q 12 h, for up to 14 days, in patients with COVID-19 pneumonia and to assess to evaluate the total oxygen requirement (area under the curve) using daily supplemental oxygen flow (L/min) over 14 days (Day 1 to Day 14) as primary efficacy.NCT04467840ABC-201Phase II/ⅢCOVID-19Lung InfectionOpaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase II/Ⅲ Study, in Adult Subjects Hospitalized With Severe SARS-CoV-2 Positive Pneumonia230Drug: OpaganibDrug: PlaceboA phase II/Ⅲ multi-center randomized, double-blind,parallel arm, placebo- controlled study in Adult Subjects Hospitalized with Severe SARS-CoV-2Positive Pneumonia to determine the potential of opaganib to improve and/or stabilize the clinical status of the patient.RedHill Biopharma unpublished dataABC-109Phase IhealthysubjectsSingle-Dose, Open-Label, Randomized, Three-Period Crossover Study to Evaluate the Effect of Food and Nasogastric Administration on the Pharmacokinetics of ABC294640 in Healthy Subjects23 healthy participantsOpaganibAssessment of the effect of a standardized meal on the absorption and bioavailability of opaganib. Table 2Clinical studies of opaganib.Table 2IDPhaseConditionsOfficial TitleSubjects TreatedIntervention/TreatmentPrimary ObjectiveNCT01488513ABC-101Phase IPancreatic CancerUnspecified Adult Solid Tumor, Protocol SpecificOpen-Label, Dose-Escalation,Safety, Pharmacokinetic and Pharmacodynamic Study of Opaganib in Patients with Advanced Solid Tumors21OpaganibTo assess safety and determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLT) of opaganib in patients with solid organ tumors.NCT02757326ABC-103Phase Ib/IIRefractory or RelapsedMultiple MyelomaA Phase Ib/II Safety and Efficacy Study of Opaganib in Patients With Refractory or Relapsed Multiple Myeloma Who Have Previously Been Treated With Proteasome Inhibitors and Immunomodulatory Drugs13OpaganibAssess overall treatment response rate and overall survival in patients with relapsed or refractory multiple myeloma treated with single-agent opaganib.NCT04207255ABC-107APhase IIProstateCancerA Phase II Study of the Addition of Opaganib to Androgen Antagonists in Patients With Prostate Cancer Progression on Enzalutamide or Abiraterone61OpaganibAbirateroneEnzalutamideTo measure the proportion of patients with disease control during opaganib (plus abiraterone or enzalutamide) therapy, using a composite metric based on PSA, bone scan, and RECIST measurements per Prostate Cancer Working Group3 (PCWG3) criteria. For purposes of this study, disease control is defined as stable disease or better after four cycles (16 weeks) of treatment.NCT03377179ABC-108Phase I/IIACholangiocarcinomaCholangiocarcinoma Non-resectableCholangiocarcinoma, PerihilarCholangiocarcinoma, ExtrahepaticCholangiocarcinoma, IntrahepaticStudy of Opaganib Alone and in Combination with Hydroxychloroquine Sulfatein the Treatment of Patients with Advanced,Unresectable Intra-hepatic, Perihilar and Extra-HepaticCholangiocarcinoma65OpaganibHydroxychloroquine Sulfate 200 MGPart 1: determine the Response Rate (RR) of cholangiocarcinoma defined as objective responses, ie complete and partial responses plus stable disease(SD) of at least 4 months to treatment with opaganib.Part 2: determine Durable Disease Control Rate (DCCR) of cholangiocarcinoma, defined as a DCR of at least a period of ≥4 4 months of treatment with opaganib and HCQ.NCT04414618ABC-110Phase IIACoronavirus InfectionsOpaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase 2a Study, in Adult Subjects Hospitalized With SARS-CoV-2 Positive Pneumonia22OpaganibPlaceboPhase 2a Proof of concept study. To assess the safety and tolerability of opaganib administered orally at 500 mg Q 12 h, for up to 14 days, in patients with COVID-19 pneumonia and to assess to evaluate the total oxygen requirement (area under the curve) using daily supplemental oxygen flow (L/min) over 14 days (Day 1 to Day 14) as primary efficacy.NCT04467840ABC-201Phase II/ⅢCOVID-19Lung InfectionOpaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase II/Ⅲ Study, in Adult Subjects Hospitalized With Severe SARS-CoV-2 Positive Pneumonia230Drug: OpaganibDrug: PlaceboA phase II/Ⅲ multi-center randomized, double-blind,parallel arm, placebo- controlled study in Adult Subjects Hospitalized with Severe SARS-CoV-2Positive Pneumonia to determine the potential of opaganib to improve and/or stabilize the clinical status of the patient.RedHill Biopharma unpublished dataABC-109Phase IhealthysubjectsSingle-Dose, Open-Label, Randomized, Three-Period Crossover Study to Evaluate the Effect of Food and Nasogastric Administration on the Pharmacokinetics of ABC294640 in Healthy Subjects23 healthy participantsOpaganibAssessment of the effect of a standardized meal on the absorption and bioavailability of opaganib. Clinical studies of opaganib. Oncology clinical trials A phase I clinical trial of opaganib administered to patients with advanced solid tumors (NCT01488513) was conducted to assess the safety and tolerability of the drug when given orally twice. Upgrading the starting dose of opaganib from in the Phase II Clinical Trial in Refractory or Relapsed Multiple Myeloma (NCT02757326) evaluated the overall treatment response rate and overall survival in opaganib-treated patients with relapsed or refractory multiple myeloma (Table 1). Fifty-eight percent of the evaluable patients achieved stable disease or better, and one patient experienced very good partial remission, which was associated with significantly lower plasma levels of TNF α, EGF, and VEGF. In a Phase II Study of heterolutamide or abiraterone for the treatment of patients with progressive prostate cancer with the addition of opaganib to androgen antagonists (NCT04207255), disease control was defined as stable or improved disease after four cycles (16 weeks) of treatment. In the Phase I/IIA Study of opaganib alone and in combination with hydroxychloroquine sulfate for the treatment of patients with advanced, unresectable intrahepatic, periportal, and extrahepatic cholangiocarcinoma (NCT03377179), complete and partial response (cr, pr) plus stable disease (sd) for at least 4 months was observed. These phase I/II studies established that opaganib is well tolerated across multiple solid tumor and hematologic malignancy settings, with grade 1–2 gastrointestinal reactions being the main adverse effects, and provided preliminary evidence of single-agent activity in cholangiocarcinoma and multiple myeloma [[16], [17], [18]]. COVID-19 and antiviral clinical trials Opaganib is a SphK2 that can treat COVID-19 pneumonia, as demonstrated in a randomized, double-blind, placebo-controlled Phase IIa (NCT04414618) and Phase II/III (NCT04467840) study of the treatment of COVID-19 pneumonia resulting from SARS-CoV-2-positive pneumonia in hospitalized adult patients. Additional a randomized, placebo-controlled, double-blind, phase 2/3 clinical trial was conducted between August 2020 and July 2021 at 57 sites around the world; a total of 475 patients infected with the COVID-19 virus were randomly assigned to receive opaganib (237 patients) or placebo (238 patients). Statistical analysis of the trial data revealed that the fraction of inspired oxygen (FiO2) at baseline responded to the therapeutic effect of opaganib and corresponded to markers of disease severity. Patients (n = 117) with FiO2 levels equal to or below the median value (≤60%) after opaganib treatment had better outcomes than did those in the placebo group (n = 134). There was an increase in the proportion of patients with FiO2 ≤60% at baseline who no longer required assisted oxygenation (≥24 h) by day 14 of opaganib treatment (76.9% vs. 63.4%; nominal P = 0.033). By day 42, intubation/mechanical ventilation was reduced by 62.6% (6.84% vs. 17.91%; nominal P = 0.012), and mortality was reduced by 62% (5.98% vs. 16.7%; nominal P = 0.019), with opaganib having a therapeutic effect on the COVID-19 virus [23,41]. These clinical data demonstrate that opaganib's host-directed mechanism translates into meaningful outcomes in severely ill patients, particularly those with moderate disease severity. Ongoing and future studies On February 4, 2025, RedHill initiated a Phase II study of opaganib and darolutamide in advanced prostate cancer. The 80-patient placebo-controlled randomized Phase II study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant prostate cancer (mCRPC), testing the potentially enhancing effect of opaganib in patients with a poor prognosis. This study uses a companion lipid biomarker test (PCPro [105]) to select mCRPC patients with poor prognoses after standard-of-care treatment who may benefit from an opaganib + darolutamide combination treatment approach. The primary endpoint will be improved 12-month radiographic progression-free survival (rPFS) rate. This biomarker-guided approach represents a paradigm for precision medicine in SphK2-targeted therapy. Beyond oncology, opaganib is being evaluated in non-cancer indications including GI-ARS, sulfur mustard exposure, and phosgene inhalation injury under U.S. government programs, reflecting its potential as a medical countermeasure [48]. Conclusion In summary, opaganib has broad and specific capabilities and plays an important role in many diseases. In terms of safety, although opaganib has shown good tolerability in early trials, data from large-scale Phase III clinical trials are limited. The safety of its long-term use has not been fully evaluated. Therefore, larger, multicenter Phase III clinical trials are needed to validate its efficacy and safety and to obtain more reliable clinical data. In terms of the mechanism of action, the primary target of opaganib is SphK2; however, its specific mechanism of action in various diseases has not been fully elucidated. Consequently, studies on the mechanism of action of opaganib at the cellular and molecular levels, especially its specific targets and signaling pathways in antiviral, anti-inflammatory, and antitumor activities, are needed. Ethics approval Not applicable. Declaration of generative AI in scientific writing Not applicable. Funding information We are grateful to the 10.13039/501100007129Shandong Natural Science Foundation (Grant No. ZR2023MB080), Chunhui Program of the Ministry of Education (Grant No. HZKY20220473) and Joint Innovation Team for Clinical & Basic Research (Grant NO. 202401). CRediT authorship contribution statement Fuxun Huang: Writing – original draft. Peng Zhan: Supervision. Xiujuan Shi: Writing – original draft. Yueyang Sun: Writing – original draft. Xingbo Song: Writing – original draft. Peilu Sun: Supervision. Bo Liu: Writing – review & editing. Declaration of competing interest The authors declare no conflict of interest.